JP6085611B2 - 癌免疫療法 - Google Patents
癌免疫療法 Download PDFInfo
- Publication number
- JP6085611B2 JP6085611B2 JP2014543984A JP2014543984A JP6085611B2 JP 6085611 B2 JP6085611 B2 JP 6085611B2 JP 2014543984 A JP2014543984 A JP 2014543984A JP 2014543984 A JP2014543984 A JP 2014543984A JP 6085611 B2 JP6085611 B2 JP 6085611B2
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- therapy
- cancer
- immunostimulant
- cell death
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002619 cancer immunotherapy Methods 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 155
- 230000003308 immunostimulating effect Effects 0.000 claims description 63
- 238000002560 therapeutic procedure Methods 0.000 claims description 61
- 229960001438 immunostimulant agent Drugs 0.000 claims description 44
- 239000003022 immunostimulating agent Substances 0.000 claims description 44
- 210000004027 cell Anatomy 0.000 claims description 43
- 201000011510 cancer Diseases 0.000 claims description 41
- 238000011282 treatment Methods 0.000 claims description 40
- 239000007924 injection Substances 0.000 claims description 34
- 238000002347 injection Methods 0.000 claims description 34
- 230000037449 immunogenic cell death Effects 0.000 claims description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 210000004881 tumor cell Anatomy 0.000 claims description 21
- 238000001959 radiotherapy Methods 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 18
- 230000010108 arterial embolization Effects 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 10
- 241000186359 Mycobacterium Species 0.000 claims description 9
- 238000002428 photodynamic therapy Methods 0.000 claims description 9
- 230000001613 neoplastic effect Effects 0.000 claims description 8
- 206010039491 Sarcoma Diseases 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- 230000007850 degeneration Effects 0.000 claims description 6
- 230000005865 ionizing radiation Effects 0.000 claims description 6
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 6
- 238000002604 ultrasonography Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 230000002601 intratumoral effect Effects 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 238000001802 infusion Methods 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 230000001394 metastastic effect Effects 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 238000007674 radiofrequency ablation Methods 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 230000008029 eradication Effects 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 239000007928 intraperitoneal injection Substances 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 238000000315 cryotherapy Methods 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 238000000015 thermotherapy Methods 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 description 37
- 210000001519 tissue Anatomy 0.000 description 35
- 230000006378 damage Effects 0.000 description 29
- 239000000427 antigen Substances 0.000 description 24
- 102000036639 antigens Human genes 0.000 description 24
- 108091007433 antigens Proteins 0.000 description 24
- 230000028993 immune response Effects 0.000 description 22
- 230000030833 cell death Effects 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- 238000002271 resection Methods 0.000 description 15
- 206010028851 Necrosis Diseases 0.000 description 13
- 230000003211 malignant effect Effects 0.000 description 13
- 230000017074 necrotic cell death Effects 0.000 description 13
- 201000009030 Carcinoma Diseases 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 11
- 229960005545 IMM-101 Drugs 0.000 description 10
- 210000000987 immune system Anatomy 0.000 description 10
- 230000002163 immunogen Effects 0.000 description 10
- 230000005855 radiation Effects 0.000 description 10
- 239000003504 photosensitizing agent Substances 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 210000002421 cell wall Anatomy 0.000 description 8
- 210000004443 dendritic cell Anatomy 0.000 description 8
- 238000009169 immunotherapy Methods 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 210000001165 lymph node Anatomy 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 208000009956 adenocarcinoma Diseases 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 208000037819 metastatic cancer Diseases 0.000 description 7
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 238000002679 ablation Methods 0.000 description 6
- 230000006020 chronic inflammation Effects 0.000 description 6
- 208000037976 chronic inflammation Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000004900 autophagic degradation Effects 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 238000011517 stereotactic body radiotherapy Methods 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 4
- 241000187918 Mycobacterium obuense Species 0.000 description 4
- 241000187644 Mycobacterium vaccae Species 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 206010003571 Astrocytoma Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000005975 antitumor immune response Effects 0.000 description 3
- 210000001099 axilla Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000008102 immune modulation Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000002350 laparotomy Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- -1 neodymium yttrium aluminum Chemical compound 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000007639 printing Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000003685 thermal hair damage Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 241000187486 Mycobacterium flavescens Species 0.000 description 2
- 241001532512 Mycobacterium parafortuitum Species 0.000 description 2
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 2
- 208000002151 Pleural effusion Diseases 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 238000010317 ablation therapy Methods 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000009285 allergic inflammation Effects 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000003073 embolic effect Effects 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 210000004013 groin Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001571 immunoadjuvant effect Effects 0.000 description 2
- 239000000568 immunological adjuvant Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 238000000608 laser ablation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 208000029974 neurofibrosarcoma Diseases 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 239000013307 optical fiber Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 208000007312 paraganglioma Diseases 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000002720 stereotactic body radiation therapy Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical class N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 208000016557 Acute basophilic leukemia Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 201000009586 Basophil Adenoma Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 208000007690 Brenner tumor Diseases 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 1
- 206010050337 Cerumen impaction Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010008583 Chloroma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010058553 Diaphragmatic injury Diseases 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014958 Eosinophilic leukaemia Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 208000000527 Germinoma Diseases 0.000 description 1
- 208000008999 Giant Cell Carcinoma Diseases 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 206010019027 Haemothorax Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000002291 Histiocytic Sarcoma Diseases 0.000 description 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 206010023129 Jaundice cholestatic Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 206010072448 Malignant blue naevus Diseases 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 206010027193 Meningioma malignant Diseases 0.000 description 1
- 201000009574 Mesenchymal Chondrosarcoma Diseases 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 241000983409 Microbacterium terrae Species 0.000 description 1
- 241001314546 Microtis <orchid> Species 0.000 description 1
- 208000013811 Mueller mixed tumour Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241001467553 Mycobacterium africanum Species 0.000 description 1
- 241000187475 Mycobacterium aichiense Species 0.000 description 1
- 241000187473 Mycobacterium aurum Species 0.000 description 1
- 241000187478 Mycobacterium chelonae Species 0.000 description 1
- 241000187912 Mycobacterium diernhoferi Species 0.000 description 1
- 241001532524 Mycobacterium duvalii Species 0.000 description 1
- 241000186365 Mycobacterium fortuitum Species 0.000 description 1
- 241000187485 Mycobacterium gastri Species 0.000 description 1
- 241000187484 Mycobacterium gordonae Species 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 241000186363 Mycobacterium kansasii Species 0.000 description 1
- 241000187483 Mycobacterium komossense Species 0.000 description 1
- 241000908167 Mycobacterium lepraemurium Species 0.000 description 1
- 241000187492 Mycobacterium marinum Species 0.000 description 1
- 241000187491 Mycobacterium nonchromogenicum Species 0.000 description 1
- 241000168058 Mycobacterium peregrinum Species 0.000 description 1
- 241000187481 Mycobacterium phlei Species 0.000 description 1
- 241001509458 Mycobacterium rhodesiae Species 0.000 description 1
- 241000187489 Mycobacterium simiae Species 0.000 description 1
- 241000187480 Mycobacterium smegmatis Species 0.000 description 1
- 241001532502 Mycobacterium tokaiense Species 0.000 description 1
- 241000187476 Mycobacterium triviale Species 0.000 description 1
- 241000187917 Mycobacterium ulcerans Species 0.000 description 1
- 241000187494 Mycobacterium xenopi Species 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000009277 Neuroectodermal Tumors Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 201000005267 Obstructive Jaundice Diseases 0.000 description 1
- 208000007871 Odontogenic Tumors Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 208000026681 Paratuberculosis Diseases 0.000 description 1
- 208000009077 Pigmented Nevus Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 201000009454 Portal vein thrombosis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 206010070627 Tumour rupture Diseases 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- KZENBFUSKMWCJF-UHFFFAOYSA-N [5-[5-[5-(hydroxymethyl)-2-thiophenyl]-2-furanyl]-2-thiophenyl]methanol Chemical compound S1C(CO)=CC=C1C1=CC=C(C=2SC(CO)=CC=2)O1 KZENBFUSKMWCJF-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 208000005310 acidophil adenoma Diseases 0.000 description 1
- 208000006336 acinar cell carcinoma Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
- 201000000452 adenoid squamous cell carcinoma Diseases 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 210000002556 adrenal cortex cell Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000005904 anticancer immunity Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 201000007436 apocrine adenocarcinoma Diseases 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 201000005476 astroblastoma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 208000019493 atypical carcinoid tumor Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000011054 breast malignant phyllodes tumor Diseases 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000003763 carbonization Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000004520 cell wall skeleton Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000002939 cerumen Anatomy 0.000 description 1
- TVFDJXOCXUVLDH-YPZZEJLDSA-N cesium-131 Chemical compound [131Cs] TVFDJXOCXUVLDH-YPZZEJLDSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 201000005217 chondroblastoma Diseases 0.000 description 1
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 229940029030 dendritic cell vaccine Drugs 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000012282 endovascular technique Methods 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 201000005616 epidermal appendage tumor Diseases 0.000 description 1
- 201000010877 epithelioid cell melanoma Diseases 0.000 description 1
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 201000008825 fibrosarcoma of bone Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 208000030316 grade III meningioma Diseases 0.000 description 1
- 210000004565 granule cell Anatomy 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- QRWOVIRDHQJFDB-UHFFFAOYSA-N isobutyl cyanoacrylate Chemical compound CC(C)COC(=O)C(=C)C#N QRWOVIRDHQJFDB-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000002332 leydig cell Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000000014 lung giant cell carcinoma Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 201000006812 malignant histiocytosis Diseases 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 208000026267 malignant phyllodes tumor Diseases 0.000 description 1
- 201000000289 malignant teratoma Diseases 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000008749 mast-cell sarcoma Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 201000010225 mixed cell type cancer Diseases 0.000 description 1
- 208000029638 mixed neoplasm Diseases 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 201000005987 myeloid sarcoma Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 208000027831 neuroepithelial neoplasm Diseases 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 201000009804 nonencapsulated sclerosing carcinoma Diseases 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000027825 odontogenic neoplasm Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010210 papillary cystadenocarcinoma Diseases 0.000 description 1
- 208000024641 papillary serous cystadenocarcinoma Diseases 0.000 description 1
- 201000001494 papillary transitional carcinoma Diseases 0.000 description 1
- 208000031101 papillary transitional cell carcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 208000020351 pituitary gland basophil adenoma Diseases 0.000 description 1
- 208000031223 plasma cell leukemia Diseases 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000013368 pseudoglandular squamous cell carcinoma Diseases 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000002673 radiosurgery Methods 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 239000007845 reactive nitrogen species Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000018964 sebaceous gland cancer Diseases 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000028647 spindle cell neoplasm Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 208000026308 thyroid gland diffuse sclerosing papillary carcinoma Diseases 0.000 description 1
- 208000015191 thyroid gland papillary and follicular carcinoma Diseases 0.000 description 1
- 230000019432 tissue death Effects 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229910019901 yttrium aluminum garnet Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Radiation-Therapy Devices (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1120779.2A GB201120779D0 (en) | 2011-12-02 | 2011-12-02 | Cancer therapy |
| GB1120779.2 | 2011-12-02 | ||
| PCT/GB2012/052992 WO2013079980A1 (en) | 2011-12-02 | 2012-12-03 | Immunogenic treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014533743A JP2014533743A (ja) | 2014-12-15 |
| JP2014533743A5 JP2014533743A5 (https=) | 2016-01-28 |
| JP6085611B2 true JP6085611B2 (ja) | 2017-02-22 |
Family
ID=45509083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014543984A Active JP6085611B2 (ja) | 2011-12-02 | 2012-12-03 | 癌免疫療法 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20140356397A1 (https=) |
| EP (1) | EP2785361B1 (https=) |
| JP (1) | JP6085611B2 (https=) |
| KR (1) | KR20140097419A (https=) |
| CN (1) | CN104023733A (https=) |
| AU (1) | AU2012343536B2 (https=) |
| BR (1) | BR112014012880A2 (https=) |
| CA (1) | CA2857429A1 (https=) |
| GB (1) | GB201120779D0 (https=) |
| IL (1) | IL232890A0 (https=) |
| IN (1) | IN2014MN00955A (https=) |
| MX (1) | MX2014006511A (https=) |
| RU (1) | RU2014121335A (https=) |
| SG (1) | SG11201402396XA (https=) |
| WO (1) | WO2013079980A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11963716B2 (en) | 2010-07-19 | 2024-04-23 | Emblation Limited | Apparatus and method for the treatment of dermatological diseases or conditions |
| GB201120779D0 (en) * | 2011-12-02 | 2012-01-11 | Immodulon Therapeutics Ltd | Cancer therapy |
| GB201308325D0 (en) * | 2013-05-09 | 2013-06-19 | Immodulon Therapeutics Ltd | Cancer Therapy |
| WO2015038832A1 (en) | 2013-09-11 | 2015-03-19 | The Board Of Trustees Of The Leland Stanford Junior University | Arrays of accelerating structures and rapid imaging for facilitating rapid radiation therapies |
| JP6723153B2 (ja) | 2013-12-05 | 2020-07-15 | アールエフイーエムビー ホールディングス リミテッド ライアビリティ カンパニー | 生体内の望ましくない軟部組織を切除するシステム |
| GB201322725D0 (en) | 2013-12-20 | 2014-02-05 | Immodulon Therapeutics Ltd | Cancer therapy |
| KR102128856B1 (ko) * | 2015-01-30 | 2020-07-02 | 알에프이엠비 홀딩스, 엘엘씨 | 고주파 전기적 막 파괴를 이용하여 생명체의 바람직하지 않은 연조직을 절제하는 시스템 |
| KR20180015269A (ko) * | 2015-06-24 | 2018-02-12 | 이모듈런 테라퓨틱스 리미티드 | 암 치료에 사용하기 위한 체크포인트 저해제와 마이코박테리움 전체 세포 |
| RU2596505C1 (ru) * | 2015-07-02 | 2016-09-10 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский радиологический центр" Министерства здравоохранения Российской Федерации (ФГБУ "НМИРЦ" Минздрава России) | Способ лечения онкологических больных цитотоксическими лимфоцитами |
| US10478194B2 (en) * | 2015-09-23 | 2019-11-19 | Covidien Lp | Occlusive devices |
| EP3402517B1 (en) | 2016-01-15 | 2025-08-20 | RFEMB Holdings, LLC | Immunologic treatment of cancer by using a tumor ablation technic together with a combination of a ctla-4 inhibitor, a pd-1 inhibitor and gm-csf |
| RU2018136347A (ru) * | 2016-04-14 | 2020-05-14 | Фелдрайх Каро Руиз Аб | Аппарат для радиационной терапии, включающий модуль ионизации и источник ультрафиолетового света |
| JP2020512151A (ja) | 2017-03-28 | 2020-04-23 | エンブレーション リミテッドＥｍｂｌａｔｉｏｎ Ｌｉｍｉｔｅｄ | 狭窄の処置 |
| EP3654976A1 (en) | 2017-07-21 | 2020-05-27 | Varian Medical Systems, Inc. | Methods of use of ultra-high dose rate radiation and therapeutic agents |
| RU2664597C1 (ru) * | 2017-12-12 | 2018-08-21 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) | Способ комбинированного лечения больных первично операбельным и местно-распространенным неоперабельным раком молочной железы |
| EA202191556A1 (ru) | 2018-12-03 | 2021-10-14 | Фьюжн Фармасьютикалз Инк. | Комбинированная терапия радиоиммуноконъюгатами и ингибиторами контрольных точек |
| US20220098578A1 (en) * | 2019-01-31 | 2022-03-31 | Bar Ilan University | Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy |
| EP4082577A4 (en) * | 2019-12-27 | 2024-01-03 | Zeria Pharmaceutical Co., Ltd. | CANCER TREATMENT METHOD AND DRUG |
| EP4376945A1 (en) * | 2021-07-27 | 2024-06-05 | Immodulon Therapeutics Limited | A mycobacterium for use in cancer therapy |
| CN114367060A (zh) * | 2022-01-13 | 2022-04-19 | 深圳大学 | 激光交变电场联合治疗仪 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5207223A (en) | 1990-10-19 | 1993-05-04 | Accuray, Inc. | Apparatus for and method of performing stereotaxic surgery |
| CA2095855C (en) * | 1990-11-08 | 2003-04-29 | Graham A.W. Rook | Mycobacterium as adjuvant for antigens |
| US5458125A (en) | 1994-01-28 | 1995-10-17 | Board Of Directors Of The Leland Standford Jr. University | Treatment planning method and apparatus for radiosurgery and radiation therapy |
| AU4281200A (en) | 1999-04-23 | 2000-11-10 | Qlt Inc. | Immuno-adjuvant pdt treatment of metastatic tumors |
| US20020022032A1 (en) | 1999-04-23 | 2002-02-21 | Curry Patrick Mark | Immuno-adjuvant PDT treatment of metastatic tumors |
| AU2002353366A1 (en) * | 2001-12-10 | 2003-06-23 | Bakulesh Mafatlal Khamar | The process of manufacturing a pharmaceutical composition useful for management of cancer |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| EP1575500A4 (en) | 2002-07-12 | 2007-01-03 | Univ Johns Hopkins | MESOTHELIN VACCINE AND MODEL SYSTEMS |
| CA2626547A1 (en) | 2005-10-21 | 2007-05-03 | Medical College Of Georgia Research Institute, Inc. | The induction of indoleamine 2,3-dioxygenase in dendritic cells by tlr ligands and uses thereof |
| US20080318252A1 (en) | 2007-04-23 | 2008-12-25 | Scott Kachlany | Rapid assay to test anti-cancer drugs under physiological conditions |
| GB0526033D0 (en) | 2005-12-21 | 2006-02-01 | Bioeos Ltd | Method |
| US8557257B2 (en) * | 2006-03-24 | 2013-10-15 | Oncovac Inc. | Mycobacterial immunotherapy for cancer treatment |
| WO2008110491A2 (en) | 2007-03-09 | 2008-09-18 | University Of Basel | Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2012122471A2 (en) * | 2011-03-09 | 2012-09-13 | The Johns Hopkins University | Compounds and methods of use in ablative radiotherapy |
| PL2172211T3 (pl) * | 2008-10-01 | 2015-05-29 | Immatics Biotechnologies Gmbh | Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka |
| US8367075B2 (en) | 2010-07-02 | 2013-02-05 | Indian Institute Of Science | Synergistic combination and method thereof |
| WO2012177624A2 (en) | 2011-06-21 | 2012-12-27 | The Johns Hopkins University | Focused radiation for augmenting immune-based therapies against neoplasms |
| GB201120779D0 (en) * | 2011-12-02 | 2012-01-11 | Immodulon Therapeutics Ltd | Cancer therapy |
| EP2620159A1 (en) | 2012-01-24 | 2013-07-31 | Institut Pasteur | Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria |
| KR20140126357A (ko) | 2012-02-01 | 2014-10-30 | 컴퓨젠 엘티디. | C1orf32 항체 및 이의 암 치료를 위한 용도 |
| US8617520B2 (en) | 2012-02-15 | 2013-12-31 | Immodulon Therapeutics Limited | Cancer therapy |
| GB201308325D0 (en) | 2013-05-09 | 2013-06-19 | Immodulon Therapeutics Ltd | Cancer Therapy |
| GB201322725D0 (en) | 2013-12-20 | 2014-02-05 | Immodulon Therapeutics Ltd | Cancer therapy |
| KR20220062143A (ko) | 2014-01-06 | 2022-05-13 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용 |
| US10975112B2 (en) | 2015-06-16 | 2021-04-13 | Hangzhou Dac Biotech Co., Ltd. | Linkers for conjugation of cell-binding molecules |
| KR20180015269A (ko) | 2015-06-24 | 2018-02-12 | 이모듈런 테라퓨틱스 리미티드 | 암 치료에 사용하기 위한 체크포인트 저해제와 마이코박테리움 전체 세포 |
| CA3104218A1 (en) | 2018-06-25 | 2020-01-02 | Immodulon Therapeutics Limited | Cancer therapy |
-
2011
- 2011-12-02 GB GBGB1120779.2A patent/GB201120779D0/en not_active Ceased
-
2012
- 2012-12-03 KR KR1020147016935A patent/KR20140097419A/ko not_active Withdrawn
- 2012-12-03 WO PCT/GB2012/052992 patent/WO2013079980A1/en not_active Ceased
- 2012-12-03 AU AU2012343536A patent/AU2012343536B2/en active Active
- 2012-12-03 JP JP2014543984A patent/JP6085611B2/ja active Active
- 2012-12-03 US US14/361,992 patent/US20140356397A1/en not_active Abandoned
- 2012-12-03 IN IN955MUN2014 patent/IN2014MN00955A/en unknown
- 2012-12-03 RU RU2014121335A patent/RU2014121335A/ru unknown
- 2012-12-03 CN CN201280059421.0A patent/CN104023733A/zh active Pending
- 2012-12-03 CA CA2857429A patent/CA2857429A1/en not_active Abandoned
- 2012-12-03 SG SG11201402396XA patent/SG11201402396XA/en unknown
- 2012-12-03 EP EP12799260.0A patent/EP2785361B1/en active Active
- 2012-12-03 MX MX2014006511A patent/MX2014006511A/es unknown
- 2012-12-03 BR BR112014012880A patent/BR112014012880A2/pt not_active IP Right Cessation
-
2014
- 2014-05-29 IL IL232890A patent/IL232890A0/en unknown
-
2018
- 2018-12-19 US US16/225,028 patent/US11318193B2/en active Active
-
2020
- 2020-06-30 US US16/916,194 patent/US11554166B2/en active Active
-
2023
- 2023-01-13 US US18/154,177 patent/US20230149525A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| GB201120779D0 (en) | 2012-01-11 |
| JP2014533743A (ja) | 2014-12-15 |
| US20200338181A1 (en) | 2020-10-29 |
| RU2014121335A (ru) | 2016-01-27 |
| US11554166B2 (en) | 2023-01-17 |
| MX2014006511A (es) | 2014-12-05 |
| CA2857429A1 (en) | 2013-06-06 |
| US20140356397A1 (en) | 2014-12-04 |
| BR112014012880A2 (pt) | 2017-06-13 |
| AU2012343536B2 (en) | 2017-08-24 |
| IL232890A0 (en) | 2014-07-31 |
| CN104023733A (zh) | 2014-09-03 |
| SG11201402396XA (en) | 2014-10-30 |
| NZ624994A (en) | 2016-10-28 |
| US20230149525A1 (en) | 2023-05-18 |
| WO2013079980A1 (en) | 2013-06-06 |
| AU2012343536A1 (en) | 2014-06-05 |
| EP2785361A1 (en) | 2014-10-08 |
| US20190224294A1 (en) | 2019-07-25 |
| IN2014MN00955A (https=) | 2015-04-24 |
| US11318193B2 (en) | 2022-05-03 |
| KR20140097419A (ko) | 2014-08-06 |
| EP2785361B1 (en) | 2018-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6085611B2 (ja) | 癌免疫療法 | |
| Yang et al. | Thermal immuno-nanomedicine in cancer | |
| Breton et al. | Microsecond and nanosecond electric pulses in cancer treatments | |
| JP2025185047A (ja) | がんの免疫学的処置 | |
| Ahmed et al. | Improved coagulation with saline solution pretreatment during radiofrequency tumor ablation in a canine model | |
| Keum et al. | Tissue ablation: applications and perspectives | |
| Bai et al. | Advancements and challenges in brain cancer therapeutics | |
| JP2014533743A5 (https=) | ||
| US20250195648A1 (en) | Therapeutic composition and method combining multiplex immunotherapy with cancer vaccine for the treatment of cancer | |
| Yu et al. | Microwave ablation induces abscopal effect via enhanced systemic antitumor immunity in colorectal cancer | |
| Tranberg | Local destruction of tumors and systemic immune effects | |
| Yan et al. | Endoscopic Ultrasound‐Guided Intratumoural Therapy for Pancreatic Cancer | |
| Peng et al. | Tumor therapeutic modes | |
| US20210154296A1 (en) | Vaccine or immunotherapeutic agent composition containing photothermally treated cell lysates as active ingredients | |
| RU2530523C2 (ru) | Способ противоопухолевой иммунотерапии | |
| NZ624994B2 (en) | Immunogenic treatment of cancer | |
| Zhu et al. | The combination of local treatment and immunotherapy | |
| 李晓松 et al. | Laser immunotherapy: Novel modality to treat cancer through specific antitumor immune response | |
| Lee et al. | Focused ultrasound as a therapeutic adjunct in pancreatic cancer: from thermal and mechanical effects to immune modulation | |
| Testoni et al. | Present and Future of Local Therapies for Unresectable Pancreatic Cancer | |
| Tsen et al. | The emerging role of endoscopists in treating unresectable pancreatic cancer | |
| Song et al. | Synergistic Effects of Cisplatin-epigel and Interstitial KTP Laser Treatment on a Xenografted Squamous Cell Carcinoma | |
| Li et al. | A multimodal neoadjuvant strategy incorporating PDT, RFA, and ICIs results in a notable pathological response and preservation of the sphincter in microsatellite stable low rectal cancer: A highly distinctive case report and literature review | |
| Shatara et al. | Emerging interventional treatments in the management of pediatric brain tumors | |
| IL300396A (en) | Dendritic cell activation therapy as an adjunct to radiation therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151201 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151201 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160906 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161202 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170105 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170130 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6085611 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |